Literature DB >> 28439891

The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.

Rosario Di Maggio1, Aurelio Maggio1.   

Abstract

This review outlines the effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major (TM). For each treatment, the strength of the evidence was documented according to the guidelines of the American College of Cardiology and the American Heart Association. Serum ferritin (SF), liver iron concentration (LIC), heart T2* signal, heart damage and survival were used to assess effectiveness. Five chelation regimens out of 10 showed Level A Evidence in controlling iron overloading, as determined by SF levels and LIC. Three out of 10 chelation regimens were able to control heart iron levels, as determined by T2* signals with Level A Evidence. Two chelation regimens were able to improve/reverse heart damage and four increased of survival with Level B Evidence. These advances mean that the current survival of TM patients is now similar to that of thalassaemia intermedia patients.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  chelation; iron overload; thalassaemia

Mesh:

Substances:

Year:  2017        PMID: 28439891     DOI: 10.1111/bjh.14712

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study.

Authors:  Hani Ayyash; Mahmoud Sirdah
Journal:  Int J Health Sci (Qassim)       Date:  2018 Nov-Dec

2.  Bio-inspired melanin nanoparticles induce cancer cell death by iron adsorption.

Authors:  James Perring; Felicity Crawshay-Williams; Cindy Huang; Helen E Townley
Journal:  J Mater Sci Mater Med       Date:  2018-11-30       Impact factor: 3.896

Review 3.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576

Review 4.  Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.

Authors:  Valeria Maria Pinto; Gian Luca Forni
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

5.  Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload.

Authors:  Raffaella Origa; Monia Cinus; Maria Paola Pilia; Barbara Gianesin; Antonietta Zappu; Valeria Orecchia; Maria Grazia Clemente; Carla Pitturru; Anna Rita Denotti; Francesco Corongiu; Simona Piras; Susanna Barella
Journal:  J Clin Med       Date:  2022-04-03       Impact factor: 4.241

Review 6.  Emerging Roles of the Iron Chelators in Inflammation.

Authors:  Alessandra Di Paola; Chiara Tortora; Maura Argenziano; Maria Maddalena Marrapodi; Francesca Rossi
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

7.  Clinical and hematological features among β-thalassemia major patients in Jazan region: A hospital-based study.

Authors:  Mohammed Mansour Khawaji; Ahmad Ali Hazzazi; Mohssen Hassen Ageeli; Yahya Hassan Mawkili; Abdulrahman Hussain Darbashi; Anwar Mohammed Ali Abo Kathiyah; Rehab Abdalrhman Humedi
Journal:  J Family Med Prim Care       Date:  2020-01-28

8.  Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.

Authors:  Frank Richard; Jan Jaap van Lier; Bernard Roubert; Teba Haboubi; Udo-Michael Göhring; Franz Dürrenberger
Journal:  Am J Hematol       Date:  2019-11-19       Impact factor: 10.047

9.  Therapeutic potential of silymarin as a natural iron-chelating agent in β-thalassemia intermedia.

Authors:  Nahid Reisi; Nafiseh Esmaeil; Marjan Gharagozloo; Behjat Moayedi
Journal:  Clin Case Rep       Date:  2022-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.